Method for Generating Pluripotent and Multipotent Cells


Research and clinical applications of induced pluripotent stem (iPS) cells are currently limited by reprogramming methods that may modify the host genome, and therefore be potentially unsafe and problematic for use in basic research, cell-based therapies, and drug-discovery applications. 

Researchers at the National Cancer Institute’s Laboratory of Pathology have overcome this challenge by using CD47 inhibiting peptides, antibodies, and morpholinos to generate and expand iPS cells.  This technology represents a safe yet highly efficient strategy for somatic cell reprogramming, and has broad applicability for basic research, disease modeling, and regenerative medicine. The NCI seeks partners interested in licensing or collaborative research to co-develop methods for generating and expanding iPS cells and lineage-committed stem cells using a single agent.



Potential Commercial Applications: Competitive Advantages:
  • iPS cell generation (human and murine)
  • Lineage-committed stem cell generation
  • Regenerative medicine
  • Stem cell therapy
 
  • Virus-free reprogramming
  • Genomic integration-free
  • Allows generation and maintenance of a ready supply of iPS cells and fate-committed stem cells using a single defined agent
  • Maintains cell growth and morphology for at least 6 months


Development Stage:
Pre-clinical (in vivo)

Related Invention(s):



Inventors:

David Roberts (NCI)  ➽ more inventions...


Intellectual Property:
US Application No. 14/390,134
Canadian Application No. 2869913

Publications:
Kaur S et al. Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors PMID: 23591719

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-086-2012
Updated: Apr 17, 2018